Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.

Sehdev AS, Kurman RJ, Kuhn E, Shih IeM.

Mod Pathol. 2010 Jun;23(6):844-55. doi: 10.1038/modpathol.2010.60. Epub 2010 Mar 12.

2.

Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.

Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM.

Am J Surg Pathol. 2015 Apr;39(4):442-53. doi: 10.1097/PAS.0000000000000352.

PMID:
25517955
3.

Are all pelvic (nonuterine) serous carcinomas of tubal origin?

Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R.

Am J Surg Pathol. 2010 Oct;34(10):1407-16. doi: 10.1097/PAS.0b013e3181ef7b16. Erratum in: Am J Surg Pathol. 2010 Dec;34(12):1891.

PMID:
20861711
4.
5.

The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, Wang TL, Shih IeM.

Am J Surg Pathol. 2012 Dec;36(12):1826-34. doi: 10.1097/PAS.0b013e31825ec07a.

6.

Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2010 Jun;34(6):829-36. doi: 10.1097/PAS.0b013e3181dcede7.

8.

Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.

Nafisi H, Ghorab Z, Ismill N, Dubé V, Plotkin A, Han G, Cesari M, Lu FI, Saad R, Khalifa M, Nofech-Mozes S.

Int J Gynecol Pathol. 2015 Sep;34(5):424-36. doi: 10.1097/PGP.0000000000000179.

PMID:
26107560
9.

Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.

Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.

Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.

PMID:
23648462
10.

Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.

Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, Karlan BY, Drapkin R.

Gynecol Oncol. 2015 Oct;139(1):104-11. doi: 10.1016/j.ygyno.2015.07.100. Epub 2015 Jul 20.

11.

TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IeM.

J Pathol. 2012 Feb;226(3):421-6. doi: 10.1002/path.3023. Epub 2011 Dec 23.

12.

Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma.

Mittal N, Srinivasan R, Gupta N, Rajwanshi A, Nijhawan R, Gautam U, Sood S, Dhaliwal L.

Indian J Pathol Microbiol. 2016 Oct-Dec;59(4):481-488. doi: 10.4103/0377-4929.191789.

13.

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ.

J Pathol. 2014 Jul;233(3):228-37. doi: 10.1002/path.4353.

14.

[Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].

Liang Y, Chen XD, Lü BJ, Zhou CY, Zhang XF, Shi HY.

Zhonghua Fu Chan Ke Za Zhi. 2011 Oct;46(10):724-8. Chinese.

PMID:
22321343
15.

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.

Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, Mutter GL, Nucci MR, Ning G, Mckeon FD, Hirsch MS, Wa X, Crum CP.

Mod Pathol. 2010 Oct;23(10):1316-24. doi: 10.1038/modpathol.2010.119. Epub 2010 Jun 18.

16.

Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.

Chene G, Cayre A, Raoelfils I, Lagarde N, Dauplat J, Penault-Llorca F.

Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:89-95. doi: 10.1016/j.ejogrb.2014.10.003. Epub 2014 Oct 14.

PMID:
25461359
17.

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.

Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IeM.

Mod Pathol. 2016 Oct;29(10):1254-61. doi: 10.1038/modpathol.2016.101. Epub 2016 Jul 22.

18.

[Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].

Wen J, Shi JL, Shen DH, Chen YX, Song QJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Jul;41(7):433-7. doi: 10.3760/cma.j.issn.0529-5807.2012.07.001. Chinese.

PMID:
22932451
19.

Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Sehdev AS, Shih IeM.

Int J Gynecol Pathol. 2012 Sep;31(5):416-22. doi: 10.1097/PGP.0b013e31824cbeb4.

20.

p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.

Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC.

Int J Gynecol Pathol. 2011 Sep;30(5):417-24. doi: 10.1097/PGP.0b013e318216d447.

PMID:
21804388

Supplemental Content

Support Center